News Image

What's going on in today's session

By Mill Chart

Last update: Apr 29, 2024

Monday's session: top gainers and losers

Top losers

TickerChangeComment
ANVS-53.58%There was a downturn in ANNOVIS BIO's (NYSE:ANVS) shares, as they experienced a 53.58% decline, closing at $8.36 during Monday's session. A press release (Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease) was released earlier today.
SWVLW-29.41%There was a downturn in PIVOTAL HOLDINGS CORP -CW27's (NASDAQ:SWVLW) shares, as they experienced a 29.41% decline, closing at $0.01 during Monday's session. Shareholders saw the stock price going 57.73% higher in the past 3 months.
JAN-26.67%JANONE INC's (NASDAQ:JAN) stock price faced a 26.67% decline, reaching $3.74 during Monday's session. In the last month the share price increased with 93.92%.
MBIO-25.66%There was a notable decline in MUSTANG BIO INC's (NASDAQ:MBIO) shares, as they dropped 25.66% to $0.23 during Monday's session. In the last month the share price dropped with 69.61%.
TCJH-23.71%Investors witnessed a 23.71% drop in TOP KINGWIN LTD-A's (NASDAQ:TCJH) stock price, which closed at $0.68 during Monday's session. The stock is trading 42.01% lower than a month ago.
FTEL-23.62%FITELL CORP's (NASDAQ:FTEL) shares fell 23.62% to $6.11. The stock is trading 183.0% higher than 3 months ago.
ATXI-22.18%AVENUE THERAPEUTICS INC's (NASDAQ:ATXI) stock price faced a 22.18% decline, reaching $4.83 during Monday's session. Earlier today the company had a press release: Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds.
CJJD-18.73%CHINA JO-JO DRUGSTORES HOLDI's (NASDAQ:CJJD) stock price faced a 18.73% decline, reaching $2.3 during Monday's session. Shareholders saw the stock price going 22.44% lower in the past 3 months.
ISUN-17.56%ISUN INC's (NASDAQ:ISUN) stock price encountered a 17.56% decline, reaching $0.14 during Monday's session. Shareholders saw the stock price going 32.8% lower in the past month.
IONM-17.46%The market experienced a 17.46% downturn in ASSURE HOLDINGS CORP's (NASDAQ:IONM) stock price, closing at $0.58 during Monday's session. Shareholders saw the stock price going 42.07% higher in the past month.

For the full top loser list go to our top losers page.

Back

MUSTANG BIO INC

NASDAQ:MBIO (5/17/2024, 7:12:09 PM)

After market: 0.3192 +0.01 (+2.31%)

0.312

+0.01 (+3.97%)

MBIO News

News Image2 days ago - InvestorPlaceMBIO Stock Earnings: Mustang Bio Beats EPS for Q1 2024

MBIO stock results show that Mustang Bio beat analyst estimates for earnings per share the first quarter of 2024.

News Image16 days ago - Mustang Bio, Inc.Mustang Bio Announces Closing of $4 Million Public Offering

Potential Additional Gross Proceeds Upon Cash Exercise of Warrants of Up to $12 Million...

News Image19 days ago - Mustang Bio, Inc.Mustang Bio Announces Pricing of $4 Million Public Offering

WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical...

News Image19 days ago - ChartmillWhat's going on in today's session

Monday's session: top gainers and losers

News Imagea month ago - InvestorPlace3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024

Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one.

News Image2 months ago - Mustang Bio, Inc.Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is...

News Image2 months ago - Mustang Bio, Inc.Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.

News Image2 months ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!

News Image2 months ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Pre-market stock movers are worth checking out on Thursday to get an idea of the hottest stocks worth watching this morning!

News Image2 months ago - Mustang Bio, Inc.Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+...

News Image4 months ago - Mustang Bio, Inc.Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

WORCESTER, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical...

News Image5 months ago - Seeking AlphaMustang Bio files to sell 2.74M shares of common stock for holders (NASDAQ:MBIO)

Mustang Bio files prospectus for resale of 2.74 million common shares; this document is not an offer to sell these securities.

MBIO Links
Follow us for more